Results 151 to 160 of about 3,591 (202)

Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) – is there still a role after comparison with palonosetron? [PDF]

Expert Opinion on Pharmacotherapy, 2017
Introduction\ud \ud Chemotherapy-induced nausea and vomiting (CINV) has a negative impact on the lives of subjects receiving chemotherapy. In 2009, the second generation 5-HT3-receptor antagonist, palonosetron, which is long-acting than granisetron, was
Sheila A Doggrell
exaly   +2 more sources

Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: The road to success

Critical Reviews in Oncology/Hematology
Over the years, advancements in antiemetic drugs have improved chemotherapy-induced nausea and vomiting (CINV) control. However, despite the antiemetics therapies, in a relevant number of adult patients (similar to 30 %), CINV is still persistent ...
Sara Pilotto, Marco Sposito
exaly   +2 more sources

Guidelines versus individualized care for the management of CINV [PDF]

Supportive Care in Cancer, 2018
Numerous groups have published guidelines for the prevention and management of chemotherapy-induced nausea and vomiting (CINV). The current management of CINV, however, remains suboptimal, due in part to poor adherence to existing antiemetic guidelines.
Mark Clemons, Mark Clemons
exaly   +3 more sources

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)

Annals of Oncology, 2012
Background: While guidelines for preventing chemotherapy-induced nausea and vomiting (CINV) are widely available, clinical uptake of guidelines remains low.
Fausto Roila, Álvaro Rodríguez-Lescure, M Aapro   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Abstract PS13-27: Duration of chemotherapy-induced nausea and vomiting (CINV) as a predictor of later-cycle CINV

Cancer Research, 2021
Abstract Background: CINV remains a challenging chemotherapy toxicity, particularly for anthracyclines + cyclophosphamide (AC) for breast cancer. Complete response (CR), defined as no vomiting or use of rescue medication over 5 days after chemotherapy, has been the standard endpoint for successful antiemetic prophylaxis, yet duration of ...
Rudolph M. Navari, Gary Binder, Eric J. Roeland, Alexander Molassiotis, Kathryn J. Ruddy, Thomas W. LeBlanc, Dwight D. Kloth, Silvia Sebastiani, Marco Turini, Luke M. Schmerold, Xing Liu, Lee Schwartzberg   +11 more
openaire   +1 more source

Clinical Management of CINV

2016
Antiemetic guidelines have been published by NCCN [1], ASCO [2], and MASCC [3]. These guidelines form the basis for the recommendations for the management of CINV. As new information and new studies emerge, the guidelines will evolve to provide the highest quality evidence-based clinical practice.
openaire   +1 more source

Gabapentin for the Prevention of CINV

2016
Gabapentin is a gamma-aminobutyric acid (GABA) analogue initially approved by the Food and Drug Administration (FDA) in 1993 for the treatment of seizures. Gabapentin was soon found to be highly effective for treating neuropathic pain [1] and then restless legs syndrome [2] and presently is FDA approved for all three indications.
openaire   +1 more source

A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan

Gynecologic Oncology, 2016
This study was performed to investigate the occurrence of and risk factors for chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer.In total, 214 patients with gynecologic cancer who underwent highly emetogenic (HEC) or moderately emetogenic chemotherapy (MEC) were evaluated.
Mika Mizuno, Masamichi Hiura, Fumitaka Kikkawa, Fumitaka Numa, Nobuo Yaegashi, Hisashi Narahara, Daisuke Aoki, Eizo Kimura, Hisamori Kato, Mototsugu Shimokawa, Toru Sugiyama, Toshiharu Kamura   +11 more
openaire   +2 more sources

Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice

Supportive Care in Cancer, 2014
We sought to describe the impact of chemotherapy-induced nausea and vomiting (CINV) in prior cycles on CINV and chemotherapy regimen modification in subsequent cycles.Eligible patients in this multinational prospective observational study were adults (≥18 years old) receiving their first single-day highly or moderately emetogenic chemotherapy (HEC or ...
Hoon-Kyo, Kim, RueyKuen, Hsieh, Alexandre, Chan, Shiying, Yu, Baohui, Han, Yunong, Gao, Ana, Baños, Xiaoyan, Ying, Thomas A, Burke, Dorothy M K, Keefe   +9 more
openaire   +2 more sources

CINV in the UK: a prospective audit of patient experience

British Journal of Nursing, 2011
Chemotherapy induces nausea and vomiting in a significant number of cancer patients across the world each day. Unfortunately patients tend to be at home and away from the specialist oncology centres when the symptoms are at their worst. This leads to a disconnect between what health professionals predict will happen to patients and what patients ...
openaire   +2 more sources